BUSINESS

Novartis Eager to See More 1st Approvals in Japan despite Pricing Headache

September 14, 2016

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Novartis Pharma is committed to drug development in Japan and willing to seek the world’s first approval in the country for its new products despite challenges it might face on the pricing front, President Dirk Kosche vowed on September 13.…

To read the full story

Novartis Japan Chief Vows All-Out Effort to Regain Trust
June 10, 2015

BUSINESS

DMD Gene Therapy Elevidys Hits Japan Market at Record Price
February 20, 2026
Bayer Eyes Kerendia as Standard Therapy for CKM Syndrome
February 20, 2026
Enhertu Accepted for EU Review in Post-Neoadjuvant HER2 Breast Cancer
February 20, 2026
SymBio Receives Grant for Antiviral Brincidofovir
February 20, 2026
Over 40% of Breast Surgeons Largely Unaware of Clinical Trials: Survey
February 20, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…

COMMENTARY

Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?

By Hayate Horiguchi

Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…